Gujarat Magazine

Shingles Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | EyeGene Inc., Wintermute Biomedical, Immorna Biotherapeutics, ICON plc, Zhuhai Trinomab

 Breaking News
  • No posts were found

Shingles Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | EyeGene Inc., Wintermute Biomedical, Immorna Biotherapeutics, ICON plc, Zhuhai Trinomab

January 15
10:00 2024
Shingles Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | EyeGene Inc., Wintermute Biomedical, Immorna Biotherapeutics, ICON plc, Zhuhai Trinomab
DelveInsight’s “Shingles Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Shingles, historical and forecasted epidemiology as well as the Shingles market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Shingles Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Shingles, historical and forecasted epidemiology as well as the Shingles market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Shingles market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Shingles Market Forecast

 

Some of the key facts of the Shingles Market Report: 

  • The Shingles market size was valued approximately USD 8500 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 2022, the United States had over 100 million individuals in the healthy population who were considered at risk for herpes zoster. According to DelveInsight’s projections, this number is anticipated to rise to over 160 million by the year 2032.
  • Evaluations indicated that within European countries, Germany had the largest pool of eligible patients for herpes zoster vaccination, totaling over 25 million people in 2022. This number is anticipated to grow further by 2032.
  • In the seven major markets (7MM), Spain had the smallest count of healthy individuals at risk for herpes zoster. In 2022, the estimated number of this at-risk population in Spain was around 18 million.
  • Key Shingles Companies: Curevo Inc, EyeGene Inc., Wintermute Biomedical, Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others
  • Key Shingles Therapies: CRV-101, EG-HZ, Solexan, JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
  • The Shingles market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Shingles pipeline products will significantly revolutionize the Shingles market dynamics.

 

Shingles Overview

Herpes zoster (HZ), commonly known as Shingles, is a neurological and dermatological condition typically resulting from the reactivation of the varicella-zoster virus (VZV). This reactivation occurs from a latent infection in the ganglia of dorsal sensory or cranial nerves, following the initial VZV infection earlier in life. Once reactivated, the virus travels along a nerve pathway to the skin, leading to the development of a rash.

 

Get a Free sample for the Shingles Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/shingles-market

 

Shingles Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Shingles Epidemiology Segmentation:

The Shingles market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Shingles
  • Prevalent Cases of Shingles by severity
  • Gender-specific Prevalence of Shingles
  • Diagnosed Cases of Episodic and Chronic Shingles

 

Download the report to understand which factors are driving Shingles epidemiology trends @ Shingles Epidemiology Forecast

 

Shingles Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Shingles market or expected to get launched during the study period. The analysis covers Shingles market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Shingles Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Shingles Therapies and Key Companies

  • CRV-101: Curevo Inc
  • EG-HZ: EyeGene Inc.
  • Solexan: Wintermute Biomedical
  • JCXH-105: Immorna Biotherapeutics, Inc./ICON plc
  • TNM005: Zhuhai Trinomab Pharmaceutical Co., Ltd.
  • CRV-101 Vaccine Antigen High Dose: Curevo Inc/Green Cross Corporation
  • mRNA-1468: ModernaTX, Inc.
  • PF-07915234: Pfizer
  • HZ/su vaccine: GlaxoSmithKline
  • Herpes Zoster Vaccine GSK1437173A: GlaxoSmithKline
  • Varicella Zoster Vaccine: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Shingles market share @ Shingles Treatment Landscape

 

Shingles Market Drivers

  • High demand for shingles vaccine
  • Strong global sales and distribution network

 

Shingles Market Barriers

  • Future launch of Shingrix for immuno-compromised patients
  • Launch opportunities in underdeveloped countries

 

Scope of the Shingles Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Shingles Companies: Curevo Inc, EyeGene Inc., Wintermute Biomedical, Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others
  • Key Shingles Therapies: CRV-101, EG-HZ, Solexan, JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
  • Shingles Therapeutic Assessment: Shingles current marketed and Shingles emerging therapies
  • Shingles Market Dynamics: Shingles market drivers and Shingles market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Shingles Unmet Needs, KOL’s views, Analyst’s views, Shingles Market Access and Reimbursement 

 

To know more about Shingles companies working in the treatment market, visit @ Shingles Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Shingles Market Report Introduction

2. Executive Summary for Shingles

3. SWOT analysis of Shingles

4. Shingles Patient Share (%) Overview at a Glance

5. Shingles Market Overview at a Glance

6. Shingles Disease Background and Overview

7. Shingles Epidemiology and Patient Population

8. Country-Specific Patient Population of Shingles 

9. Shingles Current Treatment and Medical Practices

10. Shingles Unmet Needs

11. Shingles Emerging Therapies

12. Shingles Market Outlook

13. Country-Wise Shingles Market Analysis (2019–2032)

14. Shingles Market Access and Reimbursement of Therapies

15. Shingles Market Drivers

16. Shingles Market Barriers

17.  Shingles Appendix

18. Shingles Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services